Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KERYX BIOPHARMACEUTICALS INCKERX · Entity 161794 | General Counsel and Secretary | February 15, 2018 | February 16, 2018 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Legal Officer | September 04, 2026 | September 04, 2026 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Chief Legal Officer | July 28, 2025 | July 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KERYX BIOPHARMACEUTICALS INC
Report date February 15, 2018 · Filed February 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,069 |
Reported balance
After 2018-02-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-15 · Sale · Disposed 5,652 · Balance 126,069 F1: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2: Includes 50,415 shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
F2: Includes 50,415 shares of restricted stock.
Kymera Therapeutics, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,254 |
Ending reported balance
After 2026-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 1,209 · Balance 55,416 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-09-04 · Sale · Disposed 3,025 · Balance 52,391 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-09-04 · Sale · Disposed 2,137 · Balance 50,254 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Relay Therapeutics, Inc.
Report date July 28, 2025 · Filed July 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 389,748 |
Reported balance
After 2025-07-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-28 · Sale · Disposed 1,637 · Balance 389,748 F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2: Includes 187,004 shares underlying RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 371,472 |
Reported balance
After 2025-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-07-29 · Sale · Disposed 18,276 · Balance 371,472 F3: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4: Includes 144,611 shares underlying RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2: Includes 187,004 shares underlying RSUs.
F3: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F4: Includes 144,611 shares underlying RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 4, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,137 | $117.57 | $251,247.09 |
DisclosureSEC source: 0001193125-26-383874 · ownership.xml · nonDerivative · entry 3 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,254 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,025 | $116.81 | $353,350.25 |
DisclosureSEC source: 0001193125-26-383874 · ownership.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,391 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,209 | $115.55 | $139,699.95 |
DisclosureSEC source: 0001193125-26-383874 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,416 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 8,250 | $0.00 Strike: $90.10 | $0.00 |
DisclosureSEC source: 0001193125-26-091986 · ownership.xml · derivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 8,250 shares Expires 2036-03-01 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 4,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-091986 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,625 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:05 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $43.30 | $0.00 |
DisclosureSEC source: 0001193125-25-195044 · ownership.xml · derivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2035-09-02 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option shall vest on September 3, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:05 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-195044 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following September 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:53 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 18,276 | $3.68 | $67,255.68 |
DisclosureSEC source: 0000950170-25-100364 · ownership.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,472 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 144,611 shares underlying RSUs. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:53 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,637 | $3.74 | $6,122.38 |
DisclosureSEC source: 0000950170-25-100364 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,748 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 187,004 shares underlying RSUs. Read SEC document |
| April 30, 2025 Filed May 1, 2025 00:23 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 12,943 | $3.00 | $38,829.00 |
DisclosureSEC source: 0000950170-25-061364 · ownership.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,385 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,392 shares of RSUs on April 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 192,510 shares underlying RSUs. Read SEC document |
| April 28, 2025 Filed May 1, 2025 00:23 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,644 | $3.17 | $5,211.48 |
DisclosureSEC source: 0000950170-25-061364 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,328 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on April 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 234,902 shares underlying RSUs. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 20:12 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 298 | $2.84 | $846.32 |
DisclosureSEC source: 0000950170-25-047717 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,972 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 240,407 shares underlying RSUs. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 02:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 20,791 | $4.42 | $91,896.22 |
DisclosureSEC source: 0000950170-25-011311 · ownership.xml · nonDerivative · entry 3 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,270 F5 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 69,570 shares of RSUs on January 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F6 · balance_after: Includes 241,399 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 139,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011311 · ownership.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,061 F3 · shares: Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · balance_after: Includes 310,969 shares underlying RSUs. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 02:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 33,688 | $4.63 | $155,975.44 |
DisclosureSEC source: 0000950170-25-011311 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,920 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 105,505 shares of restricted stock units ("RSUs") on January 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 171,828 shares underlying RSUs. Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000950170-25-005567 · ownership.xml · derivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 299 | $4.38 | $1,309.62 |
DisclosureSEC source: 0000950170-24-141599 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,608 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 277,333 shares underlying RSUs. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,632 | $6.06 | $9,889.92 |
DisclosureSEC source: 0000950170-24-118974 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,907 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on October 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 278,325 shares underlying RSUs. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 20:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 295 | $7.51 | $2,215.45 |
DisclosureSEC source: 0000950170-24-110804 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,539 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 283,831 shares underlying RSUs. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 22:42 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,638 | $8.85 | $14,496.30 |
DisclosureSEC source: 0000950170-24-088811 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,834 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on July 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 284,823 shares underlying RSUs. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:38 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 295 | $6.26 | $1,846.70 |
DisclosureSEC source: 0000950170-24-079684 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,472 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 290,328 shares underlying RSUs. Read SEC document |
| April 29, 2024 Filed Apr 30, 2024 00:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,623 | $6.38 | $10,354.74 |
DisclosureSEC source: 0000950170-24-050151 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,767 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on April 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 291,320 shares underlying RSUs. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 348 | $7.70 | $2,679.60 |
DisclosureSEC source: 0000950170-24-038655 · ownership.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,390 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 296,825 shares underlying RSUs. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,929 | $9.64 | $18,595.56 |
DisclosureSEC source: 0001209191-24-002468 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,738 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on January 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 297,817 shares underlying RSUs. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001835 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,667 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 303,323 shares underlying RSUs. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $11.51 | $3,383.94 |
DisclosureSEC source: 0001209191-23-059991 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,667 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 103,323 shares underlying RSUs. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,632 | $6.03 | $9,840.96 |
DisclosureSEC source: 0001209191-23-054016 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,961 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,505 shares of restricted stock units ("RSUs") on October 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 104,315 shares underlying RSUs. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:10 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $8.38 | $2,463.72 |
DisclosureSEC source: 0001209191-23-050857 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,593 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 109,820 shares underlying RSUs. Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 20:46 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,628 | $11.80 | $19,210.40 |
DisclosureSEC source: 0001209191-23-043834 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,887 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 110,812 shares underlying RSUs. Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 21:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $12.12 | $3,563.28 |
DisclosureSEC source: 0001209191-23-040054 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,515 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 116,318 shares underlying RSUs. Read SEC document |
| April 28, 2023 Filed May 1, 2023 20:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 863 | $11.16 | $9,631.08 |
DisclosureSEC source: 0001209191-23-026271 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,882 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on April 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 120,359 shares underlying RSUs. Read SEC document |
| April 28, 2023 Filed Jun 1, 2023 22:14 UTC Amendment | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,936 | $11.16 | $21,605.76 |
DisclosureSEC source: 0001209191-23-033410 · doc4a.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,809 F1 · shares: This amendment is being filed to correct the number of shares sold to cover the reporting person's income tax withholding obligations upon the vesting of 5,504 shares of restricted stock units ("RSUs") on April 27, 2023, which was inadvertently understated in the reporting person's original Form 4. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Due to the error described above, the reporting person's original Form 4 incorrectly reported that the number of shares held by the reporting person was 134,882, including 120,359 shares underlying RSUs. As reported in this amendment, the correct number of shares held by the reporting person is 133,809, including 117,309 shares underlying RSUs. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 20:47 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 347 | $15.36 | $5,329.92 |
DisclosureSEC source: 0001209191-23-021414 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,745 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 122,813 shares underlying RSUs. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 864 | $21.56 | $18,627.84 |
DisclosureSEC source: 0001209191-23-005687 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,092 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on January 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 123,805 shares underlying RSUs. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 73,220 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004123 · doc4.xml · derivative · entry 3 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,220 Underlying: Common Stock · 73,220 shares Expires 2033-01-16 F4 · derivative.exercise_date: Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 97,630 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004123 · doc4.xml · derivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,630 Underlying: Common Stock · 97,630 shares Expires 2033-01-16 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 85,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004123 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,956 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 126,259 shares underlying RSUs. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 9,994 | $20.00 | $199,880.00 |
DisclosureSEC source: 0001209191-23-003272 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,531 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 04, 2022. F2 · balance_after: Includes 40,834 shares underlying RSUs. Read SEC document |
| December 27, 2022 Filed Dec 28, 2022 21:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 295 | $14.49 | $4,274.55 |
DisclosureSEC source: 0001209191-22-062815 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,525 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 40,834 shares underlying RSUs. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 21:56 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 728 | $21.54 | $15,681.12 |
DisclosureSEC source: 0001209191-22-055112 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,820 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,455 shares of restricted stock units ("RSUs") on October 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 41,826 shares underlying RSUs. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 21:04 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $22.73 | $6,682.62 |
DisclosureSEC source: 0001209191-22-051539 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,548 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 44,281 shares underlying RSUs. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:42 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 734 | $21.27 | $15,612.18 |
DisclosureSEC source: 0001209191-22-043534 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,842 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on July 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 45,273 shares underlying RSUs. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 21:56 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 300 | $20.31 | $6,093.00 |
DisclosureSEC source: 0001209191-22-039656 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,576 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 47,727 shares underlying RSUs. Read SEC document |
| April 28, 2022 Filed May 3, 2022 00:03 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 708 | $25.57 | $18,103.56 |
DisclosureSEC source: 0001209191-22-026520 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,876 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on April 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 48,719 shares underlying RSUs. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 21:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 333 | $29.87 | $9,946.71 |
DisclosureSEC source: 0001209191-22-021814 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,584 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 51,173 shares underlying RSUs. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 78,540 | $0.00 Strike: $20.38 | $0.00 |
DisclosureSEC source: 0001209191-22-005645 · doc4.xml · derivative · entry 2 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,540 Underlying: Common Stock · 78,540 shares Expires 2032-01-26 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 39,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005645 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,917 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. F2 · balance_after: Includes 52,165 shares underlying RSUs. Read SEC document |
| December 31, 2021 Filed Jan 7, 2022 22:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 658 | $26.10 | $17,173.80 |
DisclosureSEC source: 0001209191-22-002471 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,647 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 31, 2021. F3 · balance_after: Includes 12,895 shares underlying RSUs. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 00:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 295 | $33.10 | $9,764.50 |
DisclosureSEC source: 0001209191-21-071308 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,989 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 12,895 shares underlying RSUs. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-064872 · doc4.xml · derivative · entry 3 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,786 Underlying: Common Stock · 6,500 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.